Drug Type Biological products |
Synonyms Virulizin-2 gamma |
Target |
Mechanism IL-17A stimulants(Interleukin 17A stimulants), TNF agonists(Tumor necrosis factor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date MX (01 Jan 1997), |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | MX | - | 01 Jan 1997 |
Kaposi Sarcoma | MX | - | 01 Jan 1997 |
Melanoma | MX | - | 01 Jan 1997 |
Pancreatic Cancer | MX | - | 01 Jan 1997 |
Renal Cell Carcinoma | MX | - | 01 Jan 1997 |
Stomach Cancer | MX | - | 01 Jan 1997 |
Uterine Cervical Cancer | MX | - | 01 Jan 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Preclinical | - | 01 Jul 2002 |
Phase 3 | 434 | (mjdohnlhml) = ffeshassnw esvokqvfum (ilsmnztahr ) | - | 20 Jun 2006 | |||
Placebo + Gemcitabine | (mjdohnlhml) = mvldbofxwo esvokqvfum (ilsmnztahr ) |